Zebra Capital Management LLC Denali Therapeutics Inc. Transaction History

Zebra Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $130,355 - $212,478	-4,495 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$42.59 - $55.02 $70,571 - $91,168	-1,657 Reduced 26.93%	4,495 $200,000
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $91,675 - $147,932	-1,891 Reduced 23.51%	6,152 $310,000
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $43,710 - $68,164	-869 Reduced 9.75%	8,043 $631,000
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $479,465 - $726,595	8,912 New	8,912 $509,000
Q3 2020 Nov 16, 2020	SELL	$23.13 - $38.84 $210,228 - $353,016	-9,089 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.01 - $28.82 $145,514 - $261,944	9,089 New	9,089 $220,000

216

115M

127K

38.3K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.6B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Zebra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Zebra Capital Management LLC with notifications on news.